Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: Outcome analysis in a series of 125 patients

V. Esposito, A. Santoro, Giuseppe Minniti, M. Salvati, G. Innocenzi, G. Lanzetta, G. Cantore

Research output: Contribution to journalArticle

Abstract

Transsphenoidal surgery (TSS) is a well recognised treatment for secreting pituitary adenomas, however a very wide variation of clinical outcomes and recurrence rates has been reported, depending on the different criteria used to define the cure. We reported the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted. One hundred and twenty-five consecutive patients with a secreting pituitary adenoma (42 PRL-, 67 GH- and 16 ACTH-secreting adenomas) who were operated on by the two same neurosurgeons were considered for the study. Biochemical remission of disease was achieved in 56% of patients; 78% for patients with microadenoma and 47% for patients with macroadenomas, respectively. No cases of mortality or major immediate postoperative complications were observed. Tumour size, high hormone levels and dural invasion were significantly correlated to a poor surgical outcome. The recurrence rates ranged between 0 and 24%, being higher for PRL-secreting tumours. In conclusion, TSS is safe and effective in secreting pituitary tumours. It is still the first treatment for GH- and ACTH-secreting adenomas, whereas in patients with prolactinomas, surgery should be reserved for cases of resistance or intolerance to dopamine agonists.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalNeurological Sciences
Volume25
Issue number5
DOIs
Publication statusPublished - Dec 2004

Fingerprint

Pituitary Neoplasms
Adrenocorticotropic Hormone
Prolactinoma
Adenoma
Recurrence
Dopamine Agonists
Neoplasms
Hormones
Mortality
Therapeutics

Keywords

  • Acromegaly
  • Cushing's disease
  • Pituitary adenoma
  • Prolactinoma
  • Transsphenoidal surgery

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours : Outcome analysis in a series of 125 patients. / Esposito, V.; Santoro, A.; Minniti, Giuseppe; Salvati, M.; Innocenzi, G.; Lanzetta, G.; Cantore, G.

In: Neurological Sciences, Vol. 25, No. 5, 12.2004, p. 251-256.

Research output: Contribution to journalArticle

Esposito, V. ; Santoro, A. ; Minniti, Giuseppe ; Salvati, M. ; Innocenzi, G. ; Lanzetta, G. ; Cantore, G. / Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours : Outcome analysis in a series of 125 patients. In: Neurological Sciences. 2004 ; Vol. 25, No. 5. pp. 251-256.
@article{35092803b63847a3a164cbee989e682a,
title = "Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: Outcome analysis in a series of 125 patients",
abstract = "Transsphenoidal surgery (TSS) is a well recognised treatment for secreting pituitary adenomas, however a very wide variation of clinical outcomes and recurrence rates has been reported, depending on the different criteria used to define the cure. We reported the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted. One hundred and twenty-five consecutive patients with a secreting pituitary adenoma (42 PRL-, 67 GH- and 16 ACTH-secreting adenomas) who were operated on by the two same neurosurgeons were considered for the study. Biochemical remission of disease was achieved in 56{\%} of patients; 78{\%} for patients with microadenoma and 47{\%} for patients with macroadenomas, respectively. No cases of mortality or major immediate postoperative complications were observed. Tumour size, high hormone levels and dural invasion were significantly correlated to a poor surgical outcome. The recurrence rates ranged between 0 and 24{\%}, being higher for PRL-secreting tumours. In conclusion, TSS is safe and effective in secreting pituitary tumours. It is still the first treatment for GH- and ACTH-secreting adenomas, whereas in patients with prolactinomas, surgery should be reserved for cases of resistance or intolerance to dopamine agonists.",
keywords = "Acromegaly, Cushing's disease, Pituitary adenoma, Prolactinoma, Transsphenoidal surgery",
author = "V. Esposito and A. Santoro and Giuseppe Minniti and M. Salvati and G. Innocenzi and G. Lanzetta and G. Cantore",
year = "2004",
month = "12",
doi = "10.1007/s10072-004-0351-z",
language = "English",
volume = "25",
pages = "251--256",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "5",

}

TY - JOUR

T1 - Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours

T2 - Outcome analysis in a series of 125 patients

AU - Esposito, V.

AU - Santoro, A.

AU - Minniti, Giuseppe

AU - Salvati, M.

AU - Innocenzi, G.

AU - Lanzetta, G.

AU - Cantore, G.

PY - 2004/12

Y1 - 2004/12

N2 - Transsphenoidal surgery (TSS) is a well recognised treatment for secreting pituitary adenomas, however a very wide variation of clinical outcomes and recurrence rates has been reported, depending on the different criteria used to define the cure. We reported the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted. One hundred and twenty-five consecutive patients with a secreting pituitary adenoma (42 PRL-, 67 GH- and 16 ACTH-secreting adenomas) who were operated on by the two same neurosurgeons were considered for the study. Biochemical remission of disease was achieved in 56% of patients; 78% for patients with microadenoma and 47% for patients with macroadenomas, respectively. No cases of mortality or major immediate postoperative complications were observed. Tumour size, high hormone levels and dural invasion were significantly correlated to a poor surgical outcome. The recurrence rates ranged between 0 and 24%, being higher for PRL-secreting tumours. In conclusion, TSS is safe and effective in secreting pituitary tumours. It is still the first treatment for GH- and ACTH-secreting adenomas, whereas in patients with prolactinomas, surgery should be reserved for cases of resistance or intolerance to dopamine agonists.

AB - Transsphenoidal surgery (TSS) is a well recognised treatment for secreting pituitary adenomas, however a very wide variation of clinical outcomes and recurrence rates has been reported, depending on the different criteria used to define the cure. We reported the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted. One hundred and twenty-five consecutive patients with a secreting pituitary adenoma (42 PRL-, 67 GH- and 16 ACTH-secreting adenomas) who were operated on by the two same neurosurgeons were considered for the study. Biochemical remission of disease was achieved in 56% of patients; 78% for patients with microadenoma and 47% for patients with macroadenomas, respectively. No cases of mortality or major immediate postoperative complications were observed. Tumour size, high hormone levels and dural invasion were significantly correlated to a poor surgical outcome. The recurrence rates ranged between 0 and 24%, being higher for PRL-secreting tumours. In conclusion, TSS is safe and effective in secreting pituitary tumours. It is still the first treatment for GH- and ACTH-secreting adenomas, whereas in patients with prolactinomas, surgery should be reserved for cases of resistance or intolerance to dopamine agonists.

KW - Acromegaly

KW - Cushing's disease

KW - Pituitary adenoma

KW - Prolactinoma

KW - Transsphenoidal surgery

UR - http://www.scopus.com/inward/record.url?scp=11244257350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244257350&partnerID=8YFLogxK

U2 - 10.1007/s10072-004-0351-z

DO - 10.1007/s10072-004-0351-z

M3 - Article

C2 - 15624082

AN - SCOPUS:11244257350

VL - 25

SP - 251

EP - 256

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 5

ER -